Sign In
Media & Investors
Skip Navigation LinksSanten > Europe > Media & Investors > News > Santen launches Ocutears® in Bulgaria
Contact
Santen Pharmaceutical welcomes your inquiries and opinions.

Santen launches Ocutears® in Bulgaria

4/9/2014
Sofia – April 9, 2014. Santen Europe announces that Ocutears®, a novel, preservative-free artificial tear to treat dry eye symptoms, is as of now available in Bulgaria.

 

Ocutears® protects, moistens and lubricates the ocular surface for prolonged relief of dry eye symptoms associated with mechanical, environmental or visual stress such as discomfort through wearing of contact lenses, air conditioning, wind, dryness of air, or intensive work in front of a computer screen.

 

The prescription-free product consists solely of biological substances, most importantly sodium hyaluronate 0.15% (HA) to stabilize the tear film. The ultrahigh molecular weight HA used in Ocutears® has unique viscoelastic properties, combining the therapeutic benefits of a 0.30% HA concentration (protection) with those of a 0.15% HA concentration (comfort). Ocutears® is intended to support corneal healing as well as corneal re-epithelialization.

 

Ocutears® comes in an easy-to-use preservative free multidose bottle that can be used for up to 6 months after the first opening. 

 

Ocutears® features:

  • Protects, moistens and lubricates the eye surface
  • Highly similar to natural tears
  • Ultrahigh molecular weight sodium hyaluronate (HA)
  • Therapeutic benefits of 0.30% HA with the comfort of 0.15% HA
  • No blurring
  • Unpreserved
  • Compatible with contact lenses

Santen already markets Ocutears® in countries such as Poland, Lithuania, Georgia, Hungary, Armenia, Latvia, Czech Republic - and now in Bulgaria.


In Europe, about 20% of patients, who visit an ophthalmologist, suffer from dry eye symptoms. Depending on age and gender, 5 to 35% of the population is affected. Women and elderly people are more frequently concerned.

About Santen

Founded in 1890, Santen is a global company headquartered in Osaka, Japan. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide. Tokyo Stock Exchange code 4536. For more information, visit www.santen.com.

Contact information

Geneviève Garrigos

Director, Corporate Communication Europe

Tel: + 33 6 65 54 60 19

genevieve.garrigos[at]​santen.fr